INLEXZO™ (gemcitabine intravesical system)
Pivotal clinical trial publications
Daneshmand S, et al. SunRISe-1 Study. TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study. J Clin Oncol. 2025 Jul 30:JCO2501651.
